Cranbrook Wealth Management’s GSK GSK Stock Holding History

Cranbrook Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Hold	508	–	–	0.01%	235
2026 Q1	$28K	Hold	508	–	–	0.01%	223
2025 Q4	$24.9K	Hold	508	–	–	﹤0.01%	231
2025 Q3	$21.9K	Hold	508	–	–	﹤0.01%	243
2025 Q2	$19.5K	Hold	508	–	–	﹤0.01%	249
2025 Q1	$19.7K	Hold	508	–	–	﹤0.01%	231
2024 Q4	$17.2K	Hold	508	–	–	﹤0.01%	236
2024 Q3	$20.8K	Hold	508	–	–	﹤0.01%	223
2024 Q2	$19.6K	Hold	508	–	–	﹤0.01%	222
2024 Q1	$21.8K	Hold	508	–	–	0.01%	195
2023 Q4	$18.8K	Hold	508	–	–	0.01%	203
2023 Q3	$18.4K	Hold	508	–	–	0.01%	193
2023 Q2	$18.1K	Hold	508	–	–	0.01%	203
2023 Q1	$18.1K	Hold	508	–	–	0.01%	203
2022 Q4	$17.9K	Hold	508	–	–	﹤0.01%	198
2022 Q3	$15K	Sell	508 -1	-0.2%	-$38	﹤0.01%	224
2022 Q2	$28K	Hold	509	–	–	0.01%	200
2022 Q1	$28K	Hold	509	–	–	0.01%	223
2021 Q4	$28K	Hold	509	–	–	0.01%	218
2021 Q3	$24K	Hold	509	–	–	0.01%	238
2021 Q2	$25K	Hold	509	–	–	0.01%	225
2021 Q1	$23K	Hold	509	–	–	0.01%	235
2020 Q4	$23K	Hold	509	–	–	0.01%	199
2020 Q3	$24K	Hold	509	–	–	0.01%	172
2020 Q2	$26K	Hold	509	–	–	0.01%	167
2020 Q1	$24K	Hold	509	–	–	0.01%	161
2019 Q4	$30K	Hold	509	–	–	0.01%	160
2019 Q3	$27K	Hold	509	–	–	0.01%	159
2019 Q2	$25K	Hold	509	–	–	0.01%	160
2019 Q1	$27K	Hold	509	–	–	0.01%	159
2018 Q4	$24K	Hold	509	–	–	0.01%	156
2018 Q3	$26K	Hold	509	–	–	0.01%	150
2018 Q2	$26K	Hold	509	–	–	0.01%	146
2018 Q1	$25K	Hold	509	–	–	0.01%	146
2017 Q4	$23K	Hold	509	–	–	0.01%	149
2017 Q3	$26K	Hold	509	–	–	0.01%	145
2017 Q2	$27K	Hold	509	–	–	0.01%	147
2017 Q1	$27K	Hold	509	–	–	0.01%	136
2016 Q4	$24K	Hold	509	–	–	0.01%	142
2016 Q3	$27K	Hold	509	–	–	0.01%	130
2016 Q2	$28K	Hold	509	–	–	0.01%	121
2016 Q1	$26K	Hold	509	–	–	0.01%	126
2015 Q4	$26K	Hold	509	–	–	0.01%	126
2015 Q3	$24K	Hold	509	–	–	0.01%	129
2015 Q2	$26K	Hold	509	–	–	0.01%	132
2015 Q1	$29K	Hold	509	–	–	0.02%	129
2014 Q4	$27K	Buy	+509	New	+$28.5K	0.02%	129
2014 Q1	–	Sell	-1,018	Closed	-$68K	–	179
2013 Q4	$68K	Buy	+1,018	New	+$66K	0.05%	98

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cranbrook Wealth Management's GSK Position: Q2 2026 in Review

Cranbrook Wealth Management held its GSK (GSK) position steady in Q2 2026 at 508 shares worth $26.6K. The position accounts for 0.01% of the portfolio, ranked #235.

Cranbrook Wealth Management first reported a position in GSK in Q4 2013 and has held it in 48 quarters since. The position peaked at $68K in Q4 2013. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cranbrook Wealth Management held 508 shares of GSK worth $26.6K as of Q2 2026.
Cranbrook Wealth Management left its GSK share count unchanged in Q2 2026.
GSK made up 0.01% of Cranbrook Wealth Management's portfolio in Q2 2026, its #235 holding.
Cranbrook Wealth Management first reported a position in GSK in Q4 2013 and has held it in 48 quarters since.
Cranbrook Wealth Management's GSK position peaked at $68K in Q4 2013.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cranbrook Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.